A recently discovered target with high potential for theranostic applications in glioma and brain metastases is prostate specific membrane antigen (PSMA); a transmembrane protein that is already successfully exploited for the treatment of prostate cancer patients [2]. Here, FOLH1 is linked to prostate carcinoma.